Viking Therapeutics, Inc.
VKTX
$33.80
-$0.64-1.86%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -11.85% | -9.56% | -1.81% | 22.31% | 51.67% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 163.12% | 191.32% | 160.63% | 105.15% | 70.71% |
| Operating Income | -163.12% | -191.32% | -160.63% | -105.15% | -70.71% |
| Income Before Tax | -211.75% | -268.33% | -227.05% | -139.43% | -77.32% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -211.75% | -268.33% | -227.05% | -139.43% | -77.32% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -211.75% | -268.33% | -227.05% | -139.43% | -77.32% |
| EBIT | -163.12% | -191.32% | -160.63% | -105.15% | -70.71% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -203.75% | -259.95% | -215.47% | -126.05% | -63.65% |
| Normalized Basic EPS | -203.61% | -259.67% | -215.18% | -125.77% | -63.72% |
| EPS Diluted | -203.75% | -259.95% | -215.47% | -126.05% | -63.65% |
| Normalized Diluted EPS | -203.61% | -259.67% | -215.18% | -125.77% | -63.72% |
| Average Basic Shares Outstanding | 2.62% | 2.09% | 3.31% | 5.45% | 7.93% |
| Average Diluted Shares Outstanding | 2.62% | 2.09% | 3.31% | 5.45% | 7.93% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |